Daily Policy Digest
|Consumer-Driven Health Plans Reduce Spending One Eighth
The Health Care Cost Institute has released its analysis of claims data for the years 2010 through 2014, comparing consumer-driven health plans with traditional health plans. CDHPs shift payment from third-party bureaucracies (that is, insurers) back to patients directly. The results continue to impress, cutting spending by one eighth, writes NCPA Senior Fellow John R. Graham...
|The Financial Crisis: Causes, Recollections and the Aftermath
The Financial Crisis of 2007-2009, and the aftermath, is the defining moment of my career in banking. Having served in government for 17 years, 10 of those in the bank regulatory arena, I managed to be present at some interesting places leading up to the events of 2007-2009, and served on the front lines of the recovery effort thereafter. Those experiences gave me insight into how federal policy affects financial markets, the private sector's recovery capabilities and the consequences of government responses, writes C.K. Lee, a former official with the Office of Thrift Supervision...
|NCPA Analysis of Sunday's Presidential Debate
The NCPA experts have been tracking all policy discussion during the debates, and will live-tweet through Sunday's debate and provide detailed analysis afterwards. After two debates, the presidential and vice presidential candidates have left us with more partisan bickering than actual policy. Their discussion of national security and foreign policy left several gaps in need of filling. They name-checked Social Security, but offered no real solutions. And health care -- a problem that impacts Americans on a day-to-day basis - has been startlingly absent from the debates.
|Who Benefits From The "Right to Try" Experimental Medicines?
Thirty-one states have now passed laws giving patients the "Right to Try" experimental medicines. However, they do not appear to be getting the medicines. There are two problems and one solution, according to NCPA Senior Fellow John R. Graham...
|NCPA Statement on Vice Presidential Debate
The ideas presented last night defined each potential administration; from Senator Kaine we heard a promise of more government, and from Governor Pence, we heard a plea for less. While the Vice Presidential debate was a decidedly more thoughtful discussion about critical policy issues, we’re still not clear whether either administration has a detailed plan for solving the aforementioned critical issues, writes James H. Amos, NCPA President & CEO...
|NCPA Analysis of the Vice Presidential Debate Tonight
National Center for Policy Analysis policy experts will be providing analysis during and after the next three debates, starting with the vice presidential debate tonight. To get the most out of tonight's vice presidential candidates' debate, follow and share NCPA policy experts on Twitter as they comment and offer real time analysis of this and the remaining two presidential candidates' debates.
|A Modest Proposal to Reduce the Price of EpiPens
Posturing politicians on Capitol Hill conducted a hearing, in which they grilled Heather Bresch, CEO of Mylan. N.V., which makes EpiPens. Prices of EpiPens have skyrocketed in the last few years. The politicians ignored a fundamental reform to the FDA's powers, which would quickly reduce prices of EpiPen, writes NCPA Senior Fellow John R. Graham...
|CAFE Standards Distort Auto Production and Push Jobs South
Once praised for refusing to accept a bailout, Ford is now taking heat for deciding build all small cars in Mexico. Ford already manufactures the Fiesta model in Mexico, and the Focus and C-Max will follow after the newly-proposed $1.6 billion plant is finished. Given that Ford sales have risen strongly since the recession, what is the reason for this change in direction? The easy answer -- labor costs. However, it is also likely that government regulations have helped them to shift jobs south, writes NCPA Contributor Matthew Ruland...
|A Health Care Legacy Moonshot for Obama
President Obama has an opportunity to win a positive legacy in health care. Legislation modernizing the FDA, the 21st Century Cures Act, is being fumbled inches away from the Congressional end zone. Presidential leadership is needed, writes NCPA Senior Fellow John R. Graham...
|Occupations: A Hierarchy of Regulatory Options
Government regulation has been shown to stifle innovation and entrepreneurship, thus reducing competition. In contrast, empirical studies of deregulated, competitive industries show that innovation creates greater deregulated price reductions, while market-based incentives lower costs, improve quality, and develop new products and services, writes NCPA Senior Fellow Thomas Hemphill...